Merck KGaA lung cancer drug is 3rd on U.S. watchdog's priority lane
Merck KGaA's prospective lung cancer treatment tepotinib became the third drug against a rare and aggressive subtype of the disease that won U.S. Food and Drug Administration's breakthrough therapy designation. [Source]
Publication Date:Origin: reuters.com
Category: companyNews
Topics: cancer, Merck, therapy designation, breakthrough, Administration's, that won, disease, subtype, aggressive, against, third drug, became, tepotinib, treatment, KGaA's prospective, priority, watchdog's